Absci Corporation and AstraZeneca join forces to utilize AI for an antibody targeting cancer treatment. Absci’s Integrated Drug Creation™ blends AI and lab tech to swiftly design and validate antibodies, aiming to revolutionize drug discovery in a six-week cycle. AstraZeneca’s investment and expertise support Absci’s AI-driven approach. This collaboration seeks to overcome previous drug development hurdles, potentially revolutionizing cancer treatment and expediting hope for global patients through AI-powered drug discovery.
What You Should Know:
– Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
– This partnership combines Absci’s cutting-edge Integrated Drug Creation™ platform with AstraZeneca’s oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Absci’s AI Engine Takes the Lead
Absci will leverage its innovative AI technology to design a therapeutic antibody against a specific oncology target. AstraZeneca’s upfront commitment, research and development funding, milestone payments, and future royalties on product sales demonstrate their confidence in Absci’s approach.
Revolutionizing Drug Discovery with AI and Wet-Lab Integration
Absci’s Integrated Drug Creation™ platform is a powerful combination of generative AI and cutting-edge wet-lab technologies. It generates proprietary data by analyzing millions of protein-protein interactions, which then trains its AI models. These models are further refined by validating AI-designed antibodies in the real world, creating a continuous feedback loop.
This unique platform accelerates drug discovery by completing the entire cycle of data collection, AI-driven design, and wet-lab validation within an estimated six weeks. It aims to increase the success rate of developing new biologic drugs by optimizing multiple drug features simultaneously and tackling previously “undruggable” targets like GPCRs and ion channels.
The combined expertise of Absci and AstraZeneca offers a promising outlook for developing innovative cancer treatments. By harnessing the power of AI, this collaboration has the potential to significantly accelerate drug discovery and bring new hope to cancer patients worldwide.
Source: Hit Consultant